Overview

Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent needfor novel therapies cannot stem the skyrocketing costs andplummeting productivity plaguing R&D, and many key products arefacing patent expiration. Dr. Rathnam Chaguturu presents a case forcollaboration between the pharmaceutical industry and academia thatcould reverse the industry's decline. CollaborativeInnovation in Drug Discovery: Strategies for Public and PrivatePartnerships provides insight into the potential synergyof basing R&D in academia while leaving drug companies to turnhits into marketable products. As Founder and CEO ofiDDPartners, focused on pharmaceutical innovation, Foundingpresident of the International Chemical Biology Society, and SeniorDirector-Discovery Sciences, SRI International, Dr. Chaguturu hasassembled a panel of experts from around the world to weigh in onissues that affect the two driving forces in medicaladvancement. Gain global perspectives on the benefits and potential issuessurrounding collaborative innovation Discover how industries can come together to prevent another Pharma Cliff Learn how nonprofits are becoming the driving force behindinnovation Read case studies of specific academia-pharma partnerships forreal-life examples of successful collaboration Explore government initiatives that help foster cooperationbetween industry and academia Dr. Chaguturu's thirty-five years of experience inacademia and industry, managing new lead discovery projects andforging collaborative partnerships with academia, diseasefoundations, nonprofits, and government agencies lend him aninformative perspective into the issues facing pharmaceuticalprogress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and hisexpert team provide insight into the various nuances of thedebate.

Full Product Details

Author:   Rathnam Chaguturu (Center for Advanced Drug Research, SRI International, Harrisonburg, VA) ,  Ferid Murad (Nobel Laureate) ,  Ferid Murad (Nobel Laureate)
Publisher:   John Wiley & Sons Inc
Imprint:   John Wiley & Sons Inc
ISBN:  

9781118778159

ISBN 10:   1118778154
Pages:   752
Publication Date:   28 March 2014
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Electronic book text
Publisher's Status:   Active
Availability:   In stock  
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Table of Contents

Foreword xv by Ferid Murad Preface xix About the Book xxv About the Editor xxvii Contributors xxix PART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1 If I have seen further it is by standing on the shoulders ofgiants. -Isaac Newton 1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEENGOVERNMENT, INDUSTRY, AND UNIVERSITIES 3 Wyatt R. Hume 2 DIVIDED WE FALL 11 William B. Mattes 3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY21 James M. Shaeffer and Sarah MacDonald 4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31 Litao Zhang and Carl Decicco 5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIESTO DE-RISK PRECOMPETITIVE INITIATIVES 57 Anuradha Roy and Rathnam Chaguturu 6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERYAND FUTURE CHALLENGES 75 Christopher A. Lipinski PART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVECOLLABORATION 85 Governments will always play a huge part in solving bigproblems. . . . They also fund basic research, which is a crucial component ofthe innovation that improves life for everyone. -BillGates 7 THE VALUE OF UNIVERSITY-INDUSTRY PARTNERSHIPS 87 Anthony M. Boccanfuso 8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCHAPPROACHES 99 Mark A. Scheideler 9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSAPHARMACEUTICAL ASSETS PORTAL 115 Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, NathanBahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, PeterG. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P.Guo 10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE:USE OF PUBLIC-PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCECANCER THERAPY 135 Jason V. Cristofaro 11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES:LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC ANDGOVERNMENTAL INSTITUTIONS 159 John Watson 12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TODISCOVERY IMPASSE 173 Bhushan Patwardhan PART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF195 Coming together is a beginning, staying together is progress,and working together is success. -Henry Ford 13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION197 Bernard H. Munos 14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOURPIPELINE 213 Valentina Sartori, Michael Steinmann, Petra Jantzer, andMatthias Evers 15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221 Assem S. el Baghdady and Yasser M.S. el Baghdady 16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY:APPROACHES AND REQUIREMENTS 255 Monika Lessl and Khusru Asadullah 17 CLOSE CONTACT: A COLOCATION MODEL FORACADEMIC-INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267 Peter A. Covitz and Terrence D. Ruddy 18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA-INDUSTRYPARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THEBAYER-UNIVERSITY OF COLOGNE PRIVILEGEDPARTNERSHIP 279 Stefan Herzig, Marion Rozowski, and Ingo Flamme 19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FORCOLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUGDISCOVERY 303 Barry A. Bunin and Sean Ekins 20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESSAT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY319 Paul R. Eynott and Carole Fages 21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP ANDMEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341 Allen B. Reitz and Kathleen M. Czupich 22 CHEMICAL CONSULTING 355 Lester A. Mitscher PART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION367 Can't afford to innovate? Open up! -HenryChesbrough 23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369 Tonny Johnson and Sanchayita Kar 24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCHCOLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH385 Gali Hagel 25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDIFOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TOHUNTINGTON'S DISEASE 411 Allan J. Tobin 26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUTPASTEUR AS A MODEL STRATEGY 437 Spencer L. Shorte 27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONALCOLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OFSTRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC451 Thomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and MichaelR. Jackson PART V: ACADEMIC SCREENING CENTERS COME OF AGE 487 Open access high-throughput drug discovery in the public domainis a Mount Everest in the making. -Rathnam Chaguturu 28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THEERA OF ACADEMIC SCREENING CENTERS 489 Nathan S. Blow 29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLESOF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATINGCHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499 Philip Gribbon 30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT ISFLOURISHING 517 Horst Flotow and Alex Matter 31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TOSTIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533 David Camp PART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER563 Everything that can be invented has been invented.-Charles Duell 32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THETRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565 Assem S. el Baghdady 33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUGDISCOVERIES 577 Christopher Paschall 34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THEENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609 Donna Marie De Carolis PART VII: THE FINAL FRONTIER 621 No one can whistle a symphony; it takes a whole orchestra toplay it. -Halford E. Luccock 35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVETRANSLATIONAL SCIENCE AND PUBLIC-PRIVATE COLLABORATION623 Ibis Sanchez-Serrano 36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION INBIOMEDICINE 653 Elizabeth Iorns 37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ONPATIENT NEEDS AND OUTCOMES 663 Deborah E. Collyar 38 TO LEASH OR UNLEASH THE POWER OF PUBLIC-PRIVATECOLLABORATION: IN HEALTH AND DISEASE 679 Hakim Djaballah Index 687

Reviews

Author Information

RATHNAM CHAGUTURU, PHD, is the Founder& CEO of iDDPartners, a nonprofit think-tank focused onpharmaceutical innovation. He has more than thirty years ofexperience in executing new lead discovery projects and forgingdiscovery partnerships. He is the Founding President of theInternational Chemical Biology Society and Editor-in-Chief ofCombinatorial Chemistry and High Throughput Screening. Heserves on several other editorial and scientific advisory boardsalong with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national andinternational conferences, passionately advocating the virtues ofcollaborative partnerships in addressing the pharmaceuticalinnovation crisis.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions